| 摘要 |
PROBLEM TO BE SOLVED: To provide anti-obesity agents having inter alia good duration of action, high potency, and/or convenient dosing regimens including once-weekly administration, in order to overcome the severe challenge in subjects with obesity caused by diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, hepatic steatosis disease, or diabetes (including type I and type II), the anti-obesity agents restoring Leptin responsiveness.SOLUTION: An engineered polypeptide contains a particular sequence containing an albumin binding domain polypeptide (ABD) and a first peptide hormone domain (HD1) containing leptin. An engineered polypeptide further contains a first linker (L1) linking by a covalent bond with the HD1.SELECTED DRAWING: None |
